|Bid||0.000 x 100|
|Ask||0.830 x 3500|
|Day's Range||0.2150 - 0.2292|
|52 Week Range||0.2000 - 2.2500|
|Beta (3Y Monthly)||2.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 20) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX Down In ...
Cancer Genetics (CGIX) delivered earnings and revenue surprises of -43.75% and -26.58%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Rutherford, New Jersey-based company said it had a loss of 31 cents. Losses, adjusted for restructuring costs and costs related to mergers and acquisitions, came to 23 cents per ...
RUTHERFORD, N.J., Nov. 19, 2018 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular.
Cancer Genetics (CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the appointment of Glenn Miles as Chief Financial Officer, effective November 26, 2018. Additionally, Mr. Igor Gitelman, Chief Accounting Officer of the Company will be departing Cancer Genetics to pursue other opportunities. John A. Roberts, Chief Executive Officer of Cancer Genetics, commented, “Glenn joins Cancer Genetics with a wealth of financial and accounting leadership experience, which we believe will be instrumental as we continue executing on our 2018 transformation strategy and build a foundation for sustainable growth and profitability.
Cancer Genetics (CGIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cancer Genetics (CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the publication of a letter to shareholders from its Chief Executive Officer Jay Roberts. Since I took on the role as Chief Executive Officer of the Company back in February 2018, we have made several positive advances in execution of our planned strategic direction in terms of our business and operations.
Cancer Genetics (CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, and Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models, today announced a new collaboration to develop extensive precision medicine tools and platform technologies to support the development of new cancer therapeutics. Cancer Genetics will deploy its Genomics Center of Excellence to characterize Cellaria’s pipeline of commercial and custom-developed biopharma products. Cancer Genetics will leverage its biomarker and genomics testing capabilities to better understand patient diversity across clinical disease categories.
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Cancer Genetics, Inc. (CGIX) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between March 23, 2017 and April 2, 2018. Cancer Genetics, develops, commercializes, and provides molecular and biomarker-based tests and services in the U.S., Europe, and Asia.
RUTHERFORD, N.J., Sept. 25, 2018 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and.
NEW YORK , Sept. 18, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as exclusive financial advisor to NovellusDX, Ltd., a leader in functional genomics, for ...
Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, and NovellusDx, Ltd., a leader in functional genomics, today announced the signing of a definitive agreement under which NovellusDx will merge with a newly formed Israeli subsidiary of Cancer Genetics and shareholders of NovellusDx will receive stock equal to approximately 49% of the equity of Cancer Genetics on a fully diluted basis (with certain adjustments). Cancer Genetics will be the surviving entity and expects to remain listed on the Nasdaq Stock Market. This transaction will combine Cancer Genetics’ scale, expansive test portfolio and broad data set related to tumor biology, cultivated over more than a decade, with NovellusDx’s proprietary technology and machine learning capabilities to form a leading, oncology-focused precision medicine company.
The Rutherford, New Jersey-based company said it had a loss of 13 cents per share. The diagnostics company posted revenue of $7 million in the period. The company's shares closed at 98 cents. A year ago, ...
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Cancer Genetics, Inc. (NASDAQ: CGIX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern ...
On Tuesday, Cancer Genetics (NASDAQ: CGIX ) will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications. Earnings and Revenue Wall Street analysts ...
Stock Research Monitor: CGIX, CHEK, and EXAS LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on DXCM sign up now at www.wallstequities.com/registration . Today's research on WallStEquities.com ...